Skip to content
2000
Volume 22, Issue 5
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Diabetic Neuropathy (DN) is the major chronic complication in diabetic patients. The exact pathophysiological mechanisms of DN are not fully understood; however, failures in axon–Schwann cell and microvascular endothelial communication networks play major roles in DN progression. The multiple pathophysiological mechanisms of DN are regulated by microRNAs (miRNAs), including inflammation, vascularization, angiogenesis, posttranscriptional regulation, intercellular communication, and signalling pathways. Various types of miRNA affect the gene expressions within cells, but their profiles often change during DN, including SMAD, PI3K, Nuclear Factor kappa B (NF-κB), and MAPK. DN has been associated with the miRNAs-9, miRNA-106, miRNA-182, miRNA-23a, miRNA-23b, miRNA-23c, miRNA-503, miRNA-203, miRNA-145, and miRNA-126. MiRNA dysregulation is one of the first molecular changes seen in diabetics. Therefore, miRNAs hold promise as both therapeutic targets and diagnostic biomarkers. This study aims to discuss the importance of miRNA in clinical pathophysiology, diagnosis, signalling pathways, and therapeutic targets for DN.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998375284250905115146
2025-09-23
2026-04-17

  • From This Site

    /content/journals/cdr/10.2174/0115733998375284250905115146
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cdr/22/5/CDR-22-5-08.html?itemId=/content/journals/cdr/10.2174/0115733998375284250905115146&mimeType=html&fmt=ahah

References

  1. ZainoB. GoelR. DevaragudiS. PrakashA. VaghamashiY. SethiY. PatelN. KakaN. Diabetic neuropathy: Pathogenesis and evolving principles of management.Dis. Mon.202369910158210.1016/j.disamonth.2023.10158237164794
     [Google Scholar]
  2. FanB. ChoppM. ZhangZ.G. LiuX.S. Emerging roles of micrornas as biomarkers and therapeutic targets for diabetic neuropathy.Front. Neurol.20201155875810.3389/fneur.2020.55875833192992
     [Google Scholar]
  3. RanganathanK. SivasankarV. MicroRNAs - Biology and clinical applications.J. Oral Maxillofac. Pathol.201418222923410.4103/0973‑029X.14076225328304
     [Google Scholar]
  4. LeeY. AhnC. HanJ. ChoiH. KimJ. YimJ. LeeJ. ProvostP. RådmarkO. KimS. KimV.N. The nuclear RNase III Drosha initiates microRNA processing.Nature2003425695641541910.1038/nature0195714508493
     [Google Scholar]
  5. SimeoliR. FierabracciA. Insights into the role of micrornas in the onset and development of diabetic neuropathy.Int. J. Mol. Sci.20192018462710.3390/ijms2018462731540445
     [Google Scholar]
  6. SamsuN. Diabetic Nephropathy: Challenges in pathogenesis, diagnosis, and treatment.BioMed Res. Int.202120211149744910.1155/2021/149744934307650
     [Google Scholar]
  7. LvY. YaoX. LiX. OuyangY. FanC. QianY. Cell metabolism pathways involved in the pathophysiological changes of diabetic peripheral neuropathy.Neural Regen. Res.202419359860510.4103/1673‑5374.38087237721290
     [Google Scholar]
  8. RatanY. RajputA. PareekA. PareekA. KaurR. SoniaS. KumarR. SinghG. Recent advances in biomolecular patho-mechanistic pathways behind the development and progression of diabetic neuropathy.Biomedicines2024127139010.3390/biomedicines1207139039061964
     [Google Scholar]
  9. PangL. LianX. LiuH. ZhangY. LiQ. CaiY. MaH. YuX. Understanding diabetic neuropathy: Focus on oxidative stress.Oxid. Med. Cell. Longev.2020202011310.1155/2020/952463532832011
     [Google Scholar]
  10. SzostakJ. GorącyA. DurysD. DecP. ModrzejewskiA. PawlikA. The role of microrna in the pathogenesis of diabetic nephropathy.Int. J. Mol. Sci.2023247621410.3390/ijms2407621437047185
     [Google Scholar]
  11. MassaroJ.D. PolliC.D. Costa e SilvaM. AlvesC.C. PassosG.A. Sakamoto-HojoE.T. Rodrigues de Holanda MirandaW. Bispo CezarN.J. RassiD.M. CrispimF. DibS.A. Foss-FreitasM.C. PinheiroD.G. DonadiE.A. Post-transcriptional markers associated with clinical complications in Type 1 and Type 2 diabetes mellitus.Mol. Cell. Endocrinol.201949011410.1016/j.mce.2019.03.00830926524
     [Google Scholar]
  12. KenyonJ.D. SergeevaO. SomozaR.A. LiM. CaplanA.I. KhalilA.M. LeeZ. Analysis of -5p and -3p Strands of miR-145 and miR-140 During Mesenchymal Stem Cell Chondrogenic Differentiation.Tissue Eng. Part A2019251-2809010.1089/ten.tea.2017.044029676203
     [Google Scholar]
  13. SebastianiG. GuarinoE. GriecoG.E. FormichiC. Delli PoggiC. CeccarelliE. DottaF. Circulating microRNA (miRNA) expression profiling in plasma of patients with gestational diabetes mellitus reveals upregulation of miRNA miR-330-3p.Front. Endocrinol.2017834510.3389/fendo.2017.0034529312141
     [Google Scholar]
  14. TangJ. YaoD. YanH. ChenX. WangL. ZhanH. The role of micrornas in the pathogenesis of diabetic nephropathy.Int. J. Endocrinol.201920191810.1155/2019/871906031885563
     [Google Scholar]
  15. ZhuJ. HuZ. LuoY. LiuY. LuoW. DuX. LuoZ. HuJ. PengS. Diabetic peripheral neuropathy: Pathogenetic mechanisms and treatment.Front. Endocrinol.202414126537210.3389/fendo.2023.126537238264279
     [Google Scholar]
  16. GalieroR. CaturanoA. VetranoE. BecciaD. BrinC. AlfanoM. Di SalvoJ. EpifaniR. PiacevoleA. TagliaferriG. RoccoM. IadiciccoI. DocimoG. RinaldiL. SarduC. SalvatoreT. MarfellaR. SassoF.C. Peripheral neuropathy in diabetes mellitus: Pathogenetic mechanisms and diagnostic options.Int. J. Mol. Sci.2023244355410.3390/ijms2404355436834971
     [Google Scholar]
  17. YangY. ZhaoB. WangY. LanH. LiuX. HuY. CaoP. Diabetic neuropathy: Cutting-edge research and future directions.Signal Transduct. Target. Ther.202510113210.1038/s41392‑025‑02175‑140274830
     [Google Scholar]
  18. GutierrezJ. PalmaJ.A. KaufmannH. Acute sensory and autonomic neuronopathy: A devastating disorder affecting sensory and autonomic ganglia.Semin. Neurol.202040558059010.1055/s‑0040‑171384332906171
     [Google Scholar]
  19. VincentA.M. RussellJ.W. LowP. FeldmanE.L. Oxidative stress in the pathogenesis of diabetic neuropathy.Endocr. Rev.200425461262810.1210/er.2003‑001915294884
     [Google Scholar]
  20. GroteC.W. WrightD.E. A role for insulin in diabetic neuropathy.Front. Neurosci.20161058110.3389/fnins.2016.0058128066166
     [Google Scholar]
  21. NiimiN. YakoH. TakakuS. ChungS.K. SangoK. Aldose reductase and the polyol pathway in schwann cells: Old and new problems.Int. J. Mol. Sci.2021223103110.3390/ijms2203103133494154
     [Google Scholar]
  22. GargS.S. GuptaJ. Polyol pathway and redox balance in diabetes.Pharmacol. Res.202218210632610.1016/j.phrs.2022.10632635752357
     [Google Scholar]
  23. ThorneC.A. GreyA.C. LimJ.C. DonaldsonP.J. The synergistic effects of polyol pathway-induced oxidative and osmotic stress in the aetiology of diabetic cataracts.Int. J. Mol. Sci.20242516904210.3390/ijms2516904239201727
     [Google Scholar]
  24. KilanczykE. Saraswat OhriS. WhittemoreS.R. HetmanM. Antioxidant protection of nadph-depleted oligodendrocyte precursor cells is dependent on supply of reduced glutathione.ASN Neuro201684175909141666040410.1177/175909141666040427449129
     [Google Scholar]
  25. ByunK. YooY. SonM. LeeJ. JeongG.B. ParkY.M. SalekdehG.H. LeeB. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases.Pharmacol. Ther.2017177445510.1016/j.pharmthera.2017.02.03028223234
     [Google Scholar]
  26. Sifuentes-FrancoS. Pacheco-MoisésF.P. Rodríguez-CarrizalezA.D. Miranda-DíazA.G. The role of oxidative stress, mitochondrial function, and autophagy in diabetic polyneuropathy.J. Diabetes Res.2017201711510.1155/2017/167308129204450
     [Google Scholar]
  27. PitoccoD. TesauroM. AlessandroR. GhirlandaG. CardilloC. Oxidative stress in diabetes: Implications for vascular and other complications.Int. J. Mol. Sci.20131411215252155010.3390/ijms14112152524177571
     [Google Scholar]
  28. WuL. WangX.J. LuoX. ZhangJ. ZhaoX. ChenQ. Diabetic peripheral neuropathy based on Schwann cell injury: Mechanisms of cell death regulation and therapeutic perspectives.Front. Endocrinol.202415142767910.3389/fendo.2024.142767939193373
     [Google Scholar]
  29. KoyaD. KingG.L. Protein kinase C activation and the development of diabetic complications.Diabetes199847685986610.2337/diabetes.47.6.8599604860
     [Google Scholar]
  30. GonçalvesN.P. VægterC.B. AndersenH. ØstergaardL. CalcuttN.A. JensenT.S. Schwann cell interactions with axons and microvessels in diabetic neuropathy.Nat. Rev. Neurol.201713313514710.1038/nrneurol.2016.20128134254
     [Google Scholar]
  31. MeniniS. IacobiniC. VitaleM. PuglieseG. The inflammasome in chronic complications of diabetes and related metabolic disorders.Cells202098181210.3390/cells908181232751658
     [Google Scholar]
  32. NashtahosseiniZ. EslamiM. ParaandavajiE. HarajA. DowlatB.F. HosseinzadehE. OksenychV. NaderianR. Cytokine signaling in diabetic neuropathy: A key player in peripheral nerve damage.Biomedicines202513358910.3390/biomedicines1303058940149566
     [Google Scholar]
  33. WangQ. YeY. YangL. XiaoL. LiuJ. ZhangW. DuG. Painful diabetic neuropathy: The role of ion channels.Biomed. Pharmacother.202417311641710.1016/j.biopha.2024.11641738490158
     [Google Scholar]
  34. SongZ. FuD.T. ChanY.S. LeungS. ChungS.S. ChungS.K. Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress.Mol. Cell. Neurosci.200323463864710.1016/S1044‑7431(03)00096‑412932443
     [Google Scholar]
  35. HaoW. TashiroS. HasegawaT. SatoY. KobayashiT. TandoT. KatsuyamaE. FujieA. WatanabeR. MoritaM. MiyamotoK. MoriokaH. NakamuraM. MatsumotoM. AmizukaN. ToyamaY. MiyamotoT. Hyperglycemia Promotes Schwann Cell De-differentiation and De-myelination via Sorbitol Accumulation and Igf1 Protein Down-regulation.J. Biol. Chem.201529028171061711510.1074/jbc.M114.63129125998127
     [Google Scholar]
  36. DrelV.R. PacherP. StevensM.J. ObrosovaI.G. Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.Free Radic. Biol. Med.20064081454146510.1016/j.freeradbiomed.2005.12.03416631535
     [Google Scholar]
  37. FeldmanE.L. NaveK.A. JensenT.S. BennettD.L.H. New horizons in diabetic neuropathy: Mechanisms, bioenergetics, and pain.Neuron20179361296131310.1016/j.neuron.2017.02.00528334605
     [Google Scholar]
  38. Santos-BezerraD.P. SantosA.S. GuimarãesG.C. AdmoniS.N. PerezR.V. MachadoC.G. PelaesT.S. PassarelliM. MachadoU.F. QueirozM.S. da SilvaM.E.R. Correa-GiannellaM.L. Micro-RNAs 518d-3p and 618 Are Upregulated in Individuals With Type 1 Diabetes With Multiple Microvascular Complications.Front. Endocrinol.20191038510.3389/fendo.2019.0038531249556
     [Google Scholar]
  39. WangL. ChoppM. SzaladA. ZhangY. WangX. ZhangR.L. LiuX.S. JiaL. ZhangZ.G. The role of miR-146a in dorsal root ganglia neurons of experimental diabetic peripheral neuropathy.Neuroscience201425915516310.1016/j.neuroscience.2013.11.05724316060
     [Google Scholar]
  40. JiH. LuY. LiuG. ZhaoX. XuM. ChenM. Role of decreased expression of mir-155 and mir-146a in peripheral blood of type 2 diabetes mellitus patients with diabetic peripheral neuropathy.Diabetes Metab. Syndr. Obes.2024172747276010.2147/DMSO.S46740939072343
     [Google Scholar]
  41. LiY.B. WuQ. LiuJ. FanY.Z. YuK.F. CaiY. miR-199a-3p is involved in the pathogenesis and progression of diabetic neuropathy through downregulation of SerpinE2.Mol. Med. Rep.20171632417242410.3892/mmr.2017.687428677735
     [Google Scholar]
  42. XiaH. OoiL.L.P.J. HuiK.M. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.Hepatology201358262964110.1002/hep.2636923471579
     [Google Scholar]
  43. LiuY. TianM. YangY. LiH. ZhaoT. ZhuJ. MouF. CuiG. GuoH. ShaoS. Schwann cells-derived exosomal miR-21 participates in high glucose regulation of neurite outgrowth.iScience2022251010514110.1016/j.isci.2022.10514136204278
     [Google Scholar]
  44. WangQ. WangY. MintoA.W. WangJ. ShiQ. LiX. QuiggR.J. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy.FASEB J.200822124126413510.1096/fj.08‑11232618716028
     [Google Scholar]
  45. SunJ. LiZ.P. ZhangR.Q. ZhangH.M. Repression of miR-217 protects against high glucose-induced podocyte injury and insulin resistance by restoring PTEN-mediated autophagy pathway.Biochem. Biophys. Res. Commun.2017483131832410.1016/j.bbrc.2016.12.14528017719
     [Google Scholar]
  46. LiuX.S. FanB. SzaladA. JiaL. WangL. WangX. PanW. ZhangL. ZhangR. HuJ. ZhangX.M. ChoppM. ZhangZ.G. MicroRNA-146a mimics reduce the peripheral neuropathy in type 2 diabetic mice.Diabetes201766123111312110.2337/db16‑118228899883
     [Google Scholar]
  47. ChenH.Y. ZhongX. HuangX.R. MengX.M. YouY. ChungA.C.K. LanH.Y. MicroRNA-29b inhibits diabetic nephropathy in db/db mice.Mol. Ther.201422484285310.1038/mt.2013.23524445937
     [Google Scholar]
  48. HouX. XuF. ZhangC. ShuaiJ. HuangZ. LiangY. XuX. Dexmedetomidine exerts neuroprotective effects during high glucose-induced neural injury by inhibiting miR-125b.Biosci. Rep.2020406BSR2020039410.1042/BSR2020039432538430
     [Google Scholar]
  49. SunQ. ZengJ. LiuY. ChenJ. ZengQ.C. ChenY.Q. TuL.L. ChenP. YangF. ZhangM. microRNA-9 and -29a regulate the progression of diabetic peripheral neuropathy via ISL1-mediated sonic hedgehog signaling pathway.Aging20201212114461146510.18632/aging.10323032544883
     [Google Scholar]
  50. Donate-CorreaJ. Luis-RodríguezD. Martín-NúñezE. TaguaV.G. Hernández-CarballoC. FerriC. Rodríguez-RodríguezA.E. Mora-FernándezC. Navarro-GonzálezJ.F. Inflammatory targets in diabetic nephropathy.J. Clin. Med.20209245810.3390/jcm902045832046074
     [Google Scholar]
  51. StoianA. MunteanC. BabăD.F. ManeaA. DénesL. Simon-SzabóZ. KosovskiI.B. Nemes-NagyE. GligaF.I. StoianM. Update on biomarkers of chronic inflammatory processes underlying diabetic neuropathy.Int. J. Mol. Sci.202425191039510.3390/ijms25191039539408723
     [Google Scholar]
  52. BaruttaF. BelliniS. MastrocolaR. BrunoG. GrudenG. MicroRNA and microvascular complications of diabetes.Int. J. Endocrinol.2018201812010.1155/2018/689050129707000
     [Google Scholar]
  53. LiuW. AoQ. GuoQ. HeW. PengL. JiangJ. HuX. miR-9 Mediates CALHM1-activated ATP-P2X7R signal in painful diabetic neuropathy rats.Mol. Neurobiol.201754292292910.1007/s12035‑016‑9700‑126781424
     [Google Scholar]
  54. DuanZ. ZhangJ. LiJ. PangX. WangH. Inhibition of microRNA-155 reduces neuropathic pain during chemotherapeutic bortezomib via engagement of neuroinflammation.Front. Oncol.20201041610.3389/fonc.2020.0041632296644
     [Google Scholar]
  55. YangD. YangQ. WeiX. LiuY. MaD. LiJ. WanY. LuoY. The role of miR-190a-5p contributes to diabetic neuropathic pain via targeting SLC17A6.J. Pain Res.2017102395240310.2147/JPR.S13375529042815
     [Google Scholar]
  56. KarnatiH.K. PanigrahiM.K. GuttiR.K. GreigN.H. TamargoI.A. miRNAs: Key Players in neurodegenerative disorders and epilepsy.J. Alzheimers Dis.201548356358010.3233/JAD‑15039526402105
     [Google Scholar]
  57. ZhangX. GongX. HanS. ZhangY. MiR-29b protects dorsal root ganglia neurons from diabetic rat.Cell Biochem. Biophys.20147021105111110.1007/s12013‑014‑0029‑y24819309
     [Google Scholar]
  58. JiaL. WangL. ChoppM. LiC. ZhangY. SzaladA. ZhangZ.G. MiR-29c/PRKCI regulates axonal growth of dorsal root ganglia neurons under hyperglycemia.Mol. Neurobiol.201855185185810.1007/s12035‑016‑0374‑528070856
     [Google Scholar]
  59. CorradiE. BaudetM.L. In the right place at the right time: Mirnas as key regulators in developing axons.Int. J. Mol. Sci.20202122872610.3390/ijms2122872633218218
     [Google Scholar]
  60. JiaL. WangL. ChoppM. ZhangY. SzaladA. ZhangZ.G. MicroRNA 146a locally mediates distal axonal growth of dorsal root ganglia neurons under high glucose and sildenafil conditions.Neuroscience2016329435310.1016/j.neuroscience.2016.05.00527167084
     [Google Scholar]
  61. SohnE.J. ParkH.T. MicroRNA mediated regulation of schwann cell migration and proliferation in peripheral nerve injury.BioMed Res. Int.201820181710.1155/2018/819836529854793
     [Google Scholar]
  62. VerrierJ.D. Semple-RowlandS. MadorskyI. PapinJ.E. NotterpekL. Reduction of Dicer impairs Schwann cell differentiation and myelination.J. Neurosci. Res.201088122558256810.1002/jnr.2241820648646
     [Google Scholar]
  63. EhrmannA.S. ZadroA. TauschE. SchneiderC. StilgenbauerS. MertensD. The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL.Leuk. Lymphoma202465131941195310.1080/10428194.2024.239283939161195
     [Google Scholar]
  64. Ghafouri-FardS. BahroudiZ. ShooreiH. AbakA. AhinM. TaheriM. microRNA-140: A miRNA with diverse roles in human diseases.Biomed. Pharmacother.202113511125610.1016/j.biopha.2021.11125633434855
     [Google Scholar]
  65. BaruttaF. BelliniS. GuarreraS. MatulloG. SchalkwijkC. StehouwerC.D. ChaturvediN. Soedamah-MuthuS.S. DurazzoM. GrudenG. Association of serum MicroRNA-145-5p levels with microvascular complications of type 1 Diabetes: The EURODIAB prospective complications study.Diabetes Res. Clin. Pract.202219010998710.1016/j.diabres.2022.10998735820565
     [Google Scholar]
  66. XuJ. ZhengB. MaY. ZhangX. ChengJ. YangJ. LiP. ZhangJ. JingL. XuF. PI3K-AKT-mTOR signaling pathway regulates autophagy of hippocampal neurons in diabetic rats with chronic unpredictable mild stress.Behav. Brain Res.202345211455810.1016/j.bbr.2023.11455837390967
     [Google Scholar]
  67. VithianK. HurelS. Microvascular complications: Pathophysiology and management.Clin. Med.201010550550910.7861/clinmedicine.10‑5‑50521117389
     [Google Scholar]
  68. ØstergaardL. FinnerupN.B. TerkelsenA.J. OlesenR.A. DrasbekK.R. KnudsenL. JespersenS.N. FrystykJ. CharlesM. ThomsenR.W. ChristiansenJ.S. Beck-NielsenH. JensenT.S. AndersenH. The effects of capillary dysfunction on oxygen and glucose extraction in diabetic neuropathy.Diabetologia201558466667710.1007/s00125‑014‑3461‑z25512003
     [Google Scholar]
  69. BarrettE.J. LiuZ. KhamaisiM. KingG.L. KleinR. KleinB.E.K. HughesT.M. CraftS. FreedmanB.I. BowdenD.W. VinikA.I. CaselliniC.M. Diabetic microvascular disease: An endocrine society scientific statement.J. Clin. Endocrinol. Metab.2017102124343441010.1210/jc.2017‑0192229126250
     [Google Scholar]
  70. KaurP. KotruS. SinghS. MunshiA. Role of miRNAs in diabetic neuropathy: Mechanisms and possible interventions.Mol. Neurobiol.20225931836184910.1007/s12035‑021‑02662‑w35023058
     [Google Scholar]
  71. LeC.T. LeT.N-Y. NguyenT.A. The pre-miRNA cleavage assays for DICER.Methods in Enzymology692231247202310.1016/bs.mie.2023.02.023
     [Google Scholar]
  72. BhattacharyaS. AggarwalR. Pal SinghV. RamachandranS. DattaM. Downregulation of miRNAs during delayed wound healing in diabetes: Role of dicer.Mol. Med.201521184786010.2119/molmed.2014.0018626602065
     [Google Scholar]
  73. ZhengY.L. SuX. ChenY.M. GuoJ.B. SongG. YangZ. ChenP.J. WangX.Q. microRNA-based network and pathway analysis for neuropathic pain in rodent models.Front. Mol. Biosci.2022878073010.3389/fmolb.2021.78073035096965
     [Google Scholar]
  74. RioloG. CantaraS. MarzocchiC. RicciC. miRNA Targets: From prediction tools to experimental validation.Methods Protoc.202041110.3390/mps401000133374478
     [Google Scholar]
  75. KuhnD.E. MartinM.M. FeldmanD.S. TerryA.V.Jr NuovoG.J. EltonT.S. Experimental validation of miRNA targets.Methods2008441475410.1016/j.ymeth.2007.09.00518158132
     [Google Scholar]
  76. FriedliI. Baid-AgrawalS. UnwinR. MorellA. JohanssonL. HockingsP.D. Magnetic resonance imaging in clinical trials of diabetic kidney disease.J. Clin. Med.20231214462510.3390/jcm1214462537510740
     [Google Scholar]
  77. KocaT.T. Concomitance of diabetic neuropathic amyotrophy and cachexia: A case report with review of the literature.North Clin Istanb20152216517010.14744/nci.2015.5252328058361PMC5175098
     [Google Scholar]
  78. KeikhaR. Hashemi-ShahriS.M. JebaliA. The relative expression of miR-31, miR-29, miR-126, and miR-17 and their mRNA targets in the serum of COVID-19 patients with different grades during hospitalization.Eur. J. Med. Res.20212617510.1186/s40001‑021‑00544‑434256840
     [Google Scholar]
  79. WangP. YangJ. DaiS. GaoP. QiY. ZhaoX. LiuJ. WangY. GaoY. miRNA-193a-mediated WT1 suppression triggers podocyte injury through activation of the EZH2/β-catenin/NLRP3 pathway in children with diabetic nephropathy.Exp. Cell Res.2024442211423810.1016/j.yexcr.2024.11423839251057
     [Google Scholar]
  80. XuJ. BaiS. CaoY. LiuL. FangY. DuJ. LuoL. ChenM. ShenB. ZhangQ. miRNA-221-3p in endothelial progenitor cell-derived exosomes accelerates skin wound healing in diabetic mice.Diabetes Metab. Syndr. Obes.2020131259127010.2147/DMSO.S24354932368119
     [Google Scholar]
  81. McArthurK. FengB. WuY. ChenS. ChakrabartiS. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy.Diabetes20116041314132310.2337/db10‑155721357793
     [Google Scholar]
  82. ZhaoX. LingF. ZhangG. YuN. YangJ. XinX. The correlation between micrornas and diabetic retinopathy.Front. Immunol.20221394198210.3389/fimmu.2022.94198235958584
     [Google Scholar]
  83. KotA. KaczmarekR. Exosomal miRNA profiling in vitreous humor in proliferative diabetic retinopathy.Cells202212112310.3390/cells1201012336611916
     [Google Scholar]
  84. BarsantiC. LenzariniF. KusmicC. Diagnostic and prognostic utility of non-invasive imaging in diabetes management.World J. Diabetes20156679280610.4239/wjd.v6.i6.79226131322
     [Google Scholar]
  85. DhasY. ArshadN. BiswasN. JonesL. AshiliS. MicroRNA-21 silencing in diabetic nephropathy: Insights on therapeutic strategies.Biomedicines2023119258310.3390/biomedicines1109258337761024
     [Google Scholar]
  86. LatiniA. BenedittisG.D. CiccacciC. NovelliG. SpalloneV. BorgianiP. Low expression levels of miRNA-155 and miRNA-499a are associated with obesity in Type 2 diabetes.Epigenomics2024162859110.2217/epi‑2023‑032038221897
     [Google Scholar]
  87. WangL. WangB. GengX. GuoX. WangT. XuJ. JiangL. ZhenH. microRNA-125b-5p alleviated CCI-induced neuropathic pain and modulated neuroinflammation via targeting SOX11.Synapse2024785e2230610.1002/syn.2230639135278
     [Google Scholar]
  88. JankauskasS.S. GambardellaJ. SarduC. LombardiA. SantulliG. Functional role of miR-155 in the pathogenesis of diabetes mellitus and its complications.Noncoding RNA2021733910.3390/ncrna703003934287359PMC8293470
     [Google Scholar]
  89. LiuY. GaoG. YangC. ZhouK. ShenB. LiangH. JiangX. Stability of miR-126 in urine and its potential as a biomarker for renal endothelial injury with diabetic nephropathy.Int. J. Endocrinol.201420141610.1155/2014/39310924864140
     [Google Scholar]
  90. LiY. TanP. LiuQ. LiuM. WangY. KongW. SunH. ShaoX. MiRNA-133a-3p attenuates renal tubular epithelial cell injury via targeting malm1 and suppressing the notch signaling pathway in diabetic nephropathy.Cell Biochem. Biophys.20248232401241110.1007/s12013‑024‑01351‑438878099
     [Google Scholar]
  91. CaoY. CaoX. SunL. LiY. miR-206 inhibits cell proliferation and extracellular matrix accumulation by targeting hypoxia-inducible factor 1-alpha (hif-1α) in mesangial cells treated with high glucose.Med. Sci. Monit.201925100361004410.12659/MSM.91891231880296
     [Google Scholar]
  92. ChienH.Y. LeeT.P. ChenC.Y. ChiuY.H. LinY.C. LeeL.S. LiW.C. Circulating microRNA as a diagnostic marker in populations with type 2 diabetes mellitus and diabetic complications.J. Chin. Med. Assoc.201578420421110.1016/j.jcma.2014.11.00225529478
     [Google Scholar]
  93. ChaoY. GuT. ZhangZ. WuT. WangJ. BiY. The role of miRNAs carried by extracellular vesicles in type 2 diabetes and its complications.J. Diabetes2023151083885210.1111/1753‑0407.1345637583355
     [Google Scholar]
  94. HeJ. RenW. WangW. HanW. JiangL. ZhangD. GuoM. Exosomal targeting and its potential clinical application.Drug Deliv. Transl. Res.202212102385240210.1007/s13346‑021‑01087‑134973131
     [Google Scholar]
  95. LuX. XuR. DongX. BaiD. JiW. ChenX. ChenH. HouC. GaoJ. Cell-derived exosome therapy for diabetic peripheral neuropathy: A preclinical animal studies systematic review and meta-analysis.Stem Cell Res. Ther.202516129710.1186/s13287‑025‑04432‑040490808
     [Google Scholar]
  96. HeoJ.I. RyuJ. Exosomal noncoding RNA: A potential therapy for retinal vascular diseases.Mol. Ther. Nucleic Acids202435110212810.1016/j.omtn.2024.10212838356865
     [Google Scholar]
  97. AkramR. AnwarH. JavedM.S. RasulA. ImranA. MalikS.A. RazaC. KhanI.U. SajidF. ImanT. SunT. HanH.S. HussainG. Axonal regeneration: Underlying molecular mechanisms and potential therapeutic targets.Biomedicines20221012318610.3390/biomedicines1012318636551942
     [Google Scholar]
  98. WangL. LuX. SzaladA. LiuX.S. ZhangY. WangX. GolembieskiW.A. PowellB. MccannM. LuM. ChoppM. ZhangZ.G. Schwann cell-derived exosomes ameliorate peripheral neuropathy induced by ablation of dicer in Schwann cells.Front. Cell. Neurosci.202418146222810.3389/fncel.2024.146222839285940
     [Google Scholar]
  99. JiaL. ChoppM. WangL. LuX. SzaladA. ZhangZ.G. Exosomes derived from high-glucose-stimulated Schwann cells promote development of diabetic peripheral neuropathy.FASEB J.201832126911692210.1096/fj.201800597R29932869
     [Google Scholar]
  100. GhoshM. PearseD.D. Schwann cell-derived exosomal vesicles: A promising therapy for the injured spinal cord.Int. J. Mol. Sci.202324241731710.3390/ijms24241731738139147
     [Google Scholar]
  101. ZhangX. ZhangJ. RenY. SunR. ZhaiX. Unveiling the pathogenesis and therapeutic approaches for diabetic nephropathy: Insights from panvascular diseases.Front. Endocrinol.202415136848110.3389/fendo.2024.136848138455648
     [Google Scholar]
  102. Singh GrewalA. BhardwajS. PanditaD. LatherV. Singh SekhonB. Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases.Mini Rev. Med. Chem.201516212016210.2174/1389557515666150909143737
     [Google Scholar]
  103. ChongZ.Z. SouayahN. Crumbling pathogenesis and biomarkers for diabetic peripheral neuropathy.Biomedicines202513241310.3390/biomedicines1302041340002826
     [Google Scholar]
  104. KatoM. NatarajanR. MicroRNAs in diabetic nephropathy: Functions, biomarkers, and therapeutic targets.Ann. N. Y. Acad. Sci.201513531728810.1111/nyas.1275825877817
     [Google Scholar]
  105. RezaeeA. RahmanianP. NematiA. SohrabifardF. KarimiF. ElahiniaA. RanjbarpazukiA. LashkarboloukiR. DezfulianS. ZandiehM.A. SalimimoghadamS. NabaviN. RashidiM. TaheriazamA. HashemiM. HushmandiK. NF-ĸB axis in diabetic neuropathy, cardiomyopathy and nephropathy: A roadmap from molecular intervention to therapeutic strategies.Heliyon2024109e2987110.1016/j.heliyon.2024.e2987138707342
     [Google Scholar]
  106. KatoM. NatarajanR. MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy.Semin. Nephrol.201232325326010.1016/j.semnephrol.2012.04.00422835456
     [Google Scholar]
  107. BurkU. SchubertJ. WellnerU. SchmalhoferO. VincanE. SpadernaS. BrabletzT. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.EMBO Rep.20089658258910.1038/embor.2008.7418483486
     [Google Scholar]
  108. TuC. WeiL. WangL. TangY. Eight differential mirnas in dn identified by microarray analysis as novel biomarkers.Diabetes Metab. Syndr. Obes.20221590792010.2147/DMSO.S35578335359345
     [Google Scholar]
  109. ThomasH.Y. Ford VersyptA.N. Pathophysiology of mesangial expansion in diabetic nephropathy: Mesangial structure, glomerular biomechanics, and biochemical signaling and regulation.J. Biol. Eng.20221611910.1186/s13036‑022‑00299‑435918708
     [Google Scholar]
  110. Aghaei-ZarchS.M. Crosstalk between MiRNAs/lncRNAs and PI3K/AKT signaling pathway in diabetes mellitus: Mechanistic and therapeutic perspectives.Noncoding RNA Res.20249248650710.1016/j.ncrna.2024.01.00538511053
     [Google Scholar]
  111. ChawraH.S. AgarwalM. MishraA. ChandelS.S. SinghR.P. DubeyG. KukretiN. SinghM. MicroRNA-21's role in PTEN suppression and PI3K/AKT activation: Implications for cancer biology.Pathol. Res. Pract.202425415509110.1016/j.prp.2024.15509138194804
     [Google Scholar]
  112. BeraA. DasF. Ghosh-ChoudhuryN. MariappanM.M. KasinathB.S. Ghosh ChoudhuryG. Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion.Am. J. Physiol. Cell Physiol.20173134C430C44710.1152/ajpcell.00081.201728701356
     [Google Scholar]
  113. PhamV.M. Targeting PI3K/AKT and MEK/ERK pathways for synergic effects on improving features of peripheral diabetic neuropathy.J. Diabetes Investig.202415111537154410.1111/jdi.1428939162579
     [Google Scholar]
  114. LiuY. AoX. DingW. PonnusamyM. WuW. HaoX. YuW. WangY. LiP. WangJ. Critical role of FOXO3a in carcinogenesis.Mol. Cancer201817110410.1186/s12943‑018‑0856‑330045773
     [Google Scholar]
  115. Nahum-AnkoninaO. Kurtzwald-JosefsonE. CiechanoverA. WaldmanM. Shwartz-RohakerO. HochhauserE. MeyerS.J. AravotD. PhillipM. BaracY.D. Ubiquitin proteasome system role in diabetes-induced cardiomyopathy.Int. J. Mol. Sci.202324201537610.3390/ijms24201537637895057
     [Google Scholar]
  116. FhuC.W. AliA. Dysregulation of the ubiquitin proteasome system in human malignancies: A window for therapeutic intervention.Cancers2021137151310.3390/cancers1307151333805973
     [Google Scholar]
  117. KimY. KimE.K. CheyY. SongM.J. JangH.H. Targeted protein degradation: Principles and applications of the proteasome.Cells20231214184610.3390/cells1214184637508510
     [Google Scholar]
  118. PuttaS. LantingL. SunG. LawsonG. KatoM. NatarajanR. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy.J. Am. Soc. Nephrol.201223345846910.1681/ASN.201105048522223877
     [Google Scholar]
  119. XuH. SunF. LiX. SunL. Down-regulation of miR-23a inhibits high glucose-induced EMT and renal fibrogenesis by up-regulation of SnoN.Hum. Cell2018311223210.1007/s13577‑017‑0180‑z28707079
     [Google Scholar]
  120. ZhangH. LuoW. SunY. QiaoY. ZhangL. ZhaoZ. LvS. Wnt/β-Catenin signaling mediated-uch-l1 expression in podocytes of diabetic nephropathy.Int. J. Mol. Sci.2016179140410.3390/ijms1709140427571062
     [Google Scholar]
  121. SulaimanM.K. Diabetic nephropathy: Recent advances in pathophysiology and challenges in dietary management.Diabetol. Metab. Syndr.2019111710.1186/s13098‑019‑0403‑430679960
     [Google Scholar]
  122. FiorentinoL. CavaleraM. MavilioM. ConservaF. MenghiniR. GesualdoL. FedericiM. Regulation of TIMP3 in diabetic nephropathy: A role for microRNAs.Acta Diabetol.201350696596910.1007/s00592‑013‑0492‑823797704
     [Google Scholar]
  123. CasagrandeV. FedericiM. MenghiniR. TIMP3 involvement and potentiality in the diagnosis, prognosis and treatment of diabetic nephropathy.Acta Diabetol.202158121587159410.1007/s00592‑021‑01766‑y34181080
     [Google Scholar]
  124. MahlC. EgeaV. MegensR.T.A. PitschT. SantovitoD. WeberC. RiesC. RECK (reversion-inducing cysteine-rich protein with Kazal motifs) regulates migration, differentiation and Wnt/β-catenin signaling in human mesenchymal stem cells.Cell. Mol. Life Sci.20167371489150110.1007/s00018‑015‑2054‑426459448
     [Google Scholar]
  125. FengY. ChenL. LuoQ. WuM. ChenY. ShiX. Involvement of microRNA-146a in diabetic peripheral neuropathy through the regulation of inflammation.Drug Des. Devel. Ther.20181217117710.2147/DDDT.S15710929398906
     [Google Scholar]
  126. QadirM.M.F. KleinD. Álvarez-CubelaS. Domínguez-BendalaJ. PastoriR.L. The role of micrornas in diabetes-related oxidative stress.Int. J. Mol. Sci.20192021542310.3390/ijms2021542331683538
     [Google Scholar]
  127. QinW. ChungA.C.K. HuangX.R. MengX.M. HuiD.S.C. YuC.M. SungJ.J.Y. LanH.Y. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29.J. Am. Soc. Nephrol.20112281462147410.1681/ASN.201012130821784902
     [Google Scholar]
  128. LinC.J. LanY.M. OuM.Q. JiL.Q. LinS.D. Expression of miR-217 and HIF-1α/VEGF pathway in patients with diabetic foot ulcer and its effect on angiogenesis of diabetic foot ulcer rats.J. Endocrinol. Invest.201942111307131710.1007/s40618‑019‑01053‑231079353
     [Google Scholar]
  129. YuC.Y. YangC.Y. RuiZ.L. MicroRNA-125b-5p improves pancreatic β-cell function through inhibiting JNK signaling pathway by targeting DACT1 in mice with type 2 diabetes mellitus.Life Sci.2019224677510.1016/j.lfs.2019.01.03130684546
     [Google Scholar]
  130. NigiL. GriecoG.E. VentrigliaG. BruscoN. MancarellaF. FormichiC. DottaF. SebastianiG. MicroRNAs as regulators of insulin signaling: Research updates and potential therapeutic perspectives in type 2 diabetes.Int. J. Mol. Sci.20181912370510.3390/ijms1912370530469501
     [Google Scholar]
  131. JurjA. FontanaB. VaraniG. CalinG.A. Small molecules targeting microRNAs: New opportunities and challenges in precision cancer therapy.Trends Cancer202410980982410.1016/j.trecan.2024.06.00639107162
     [Google Scholar]
  132. LiuF. LouY.L. WuJ. RuanQ.F. XieA. GuoF. CuiS.P. DengZ.F. WangY. Upregulation of microRNA-210 regulates renal angiogenesis mediated by activation of VEGF signaling pathway under ischemia/perfusion injury in vivo and in vitro .Kidney Blood Press. Res.201235318219110.1159/00033105422123256
     [Google Scholar]
  133. WenW. WeiY. GaoS. Functional nucleic acids for the treatment of diabetic complications.Nanoscale Adv.20235205426543410.1039/D3NA00327B37822913
     [Google Scholar]
  134. BijkerkR. de BruinR.G. van SolingenC. van GilsJ.M. DuijsJ.M.G.J. van der VeerE.P. RabelinkT.J. HumphreysB.D. van ZonneveldA.J. Silencing of microRNA-132 reduces renal fibrosis by selectively inhibiting myofibroblast proliferation.Kidney Int.20168961268128010.1016/j.kint.2016.01.02927165825
     [Google Scholar]
  135. LicznerC. DukeK. JuneauG. EgliM. WildsC.J. Beyond ribose and phosphate: Selected nucleic acid modifications for structure–function investigations and therapeutic applications.Beilstein J. Org. Chem.20211790893110.3762/bjoc.17.7633981365
     [Google Scholar]
  136. NegeemZ. Abdel MoneimA. MahmoudB. AhmedA.E. Abd El-HameedA.M. EskandraniA.A. HasonaN.A. The implication of miR-200a and miR-132 expression and their correlations with NF-κB/TNF-alpha signaling in adults with diabetic nephropathy.Saudi J. Biol. Sci.202431510397510.1016/j.sjbs.2024.10397538544953
     [Google Scholar]
  137. WangB. YaoK. WiseA.F. LauR. ShenH.H. TeschG.H. RicardoS.D. miR-378 reduces mesangial hypertrophy and kidney tubular fibrosis via MAPK signalling.Clin. Sci.2017131541142310.1042/CS2016057128053239
     [Google Scholar]
  138. KogaK. YokoiH. MoriK. KasaharaM. KuwabaraT. ImamakiH. IshiiA. MoriK.P. KatoY. OhnoS. TodaN. SaleemM.A. SugawaraA. NakaoK. YanagitaM. MukoyamaM. MicroRNA-26a inhibits TGF-β-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy.Diabetologia20155892169218010.1007/s00125‑015‑3642‑426063197
     [Google Scholar]
  139. ZhangY. SunX. IcliB. FeinbergM.W. Emerging roles for micrornas in diabetic microvascular disease: Novel targets for therapy.Endocr. Rev.201738214516810.1210/er.2016‑112228323921
     [Google Scholar]
  140. SmythA. CallaghanB. WilloughbyC.E. O’BrienC. The role of mir-29 family in tgf-β driven fibrosis in glaucomatous optic neuropathy.Int. J. Mol. Sci.202223181021610.3390/ijms23181021636142127
     [Google Scholar]
  141. ShiJ. LiuX. JiaoY. TianJ. AnJ. ZouG. ZhuoL. MTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets.Genes Dis.202512210126010.1016/j.gendis.2024.10126039717716
     [Google Scholar]
  142. LiuX. ZhangY. LiangH. ZhangY. XuY. microRNA-499-3p inhibits proliferation and promotes apoptosis of retinal cells in diabetic retinopathy through activation of the TLR4 signaling pathway by targeting IFNA2.Gene202074114453910.1016/j.gene.2020.14453932160960
     [Google Scholar]
  143. GaoC. YangT. ShuJ. GaoX. MengC. Overexpression of miR-133a-3p reduces microglia activation by binding to GCH1, alleviating neuroinflammation and neuropathic pain.Exp. Brain Res.202524312310.1007/s00221‑024‑06956‑y39666013
     [Google Scholar]
  144. SanguinetiR. PudduA. NicolòM. TraversoC.E. CorderaR. VivianiG.L. MaggiD. MIR-126 MIMIC counteracts the increased secretion of vegf-a induced by high glucose in ARPE-19 cells.J. Diabetes Res.202120211710.1155/2021/664922233709000
     [Google Scholar]
  145. WuY. XuD. ZhuX. YangG. RenM. MiR-106a associated with diabetic peripheral neuropathy through the regulation of 12/15-LOX-mediated oxidative/nitrative stress.Curr Neurovasc Res201714211712410.2174/156720261466617040411591228393703
     [Google Scholar]
  146. El-LithyG.M. El-BaklyW.M. MatboliM. Abd-AlkhalekH.A. MasoudS.I. HamzaM. Prophylactic L-arginine and ibuprofen delay the development of tactile allodynia and suppress spinal miR-155 in a rat model of diabetic neuropathy.Transl. Res.20161778597.e110.1016/j.trsl.2016.06.00527392937
     [Google Scholar]
  147. ConteG. NguyenN.T. AlvesM. de Diego-GarciaL. KennyA. NickeA. HenshallD.C. Jimenez-MateosE.M. EngelT. P2X7 Receptor-Dependent microrna expression profile in the brain following status epilepticus in mice.Front. Mol. Neurosci.20201312710.3389/fnmol.2020.0012732982684
     [Google Scholar]
  148. ChangL.L. WangH.C. TsengK.Y. SuM.P. WangJ.Y. ChuangY.T. WangY.H. ChengK.I. Upregulation of miR-133a-3p in the sciatic nerve contributes to neuropathic pain development.Mol. Neurobiol.20205793931394210.1007/s12035‑020‑01999‑y32632603
     [Google Scholar]
  149. WuX. WangX. YinY. ZhuL. ZhangF. YangJ. Investigation of the role of miR-221 in diabetic peripheral neuropathy and related molecular mechanisms.Adv. Clin. Exp. Med.202130662363210.17219/acem/13121734018345
     [Google Scholar]
  150. HashemiM. ZandiehM.A. ZiaolhaghS. MojtabaviS. SadiF.H. KoohparZ.K. GhanbariradM. HaghighatfardA. BehroozaghdamM. KhorramiR. NabaviN. RenJ. ReiterR.J. SalimimoghadamS. RashidiM. HushmandiK. TaheriazamA. EntezariM. Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective.Biochim. Biophys. Acta Mol. Basis Dis.20231869516671410.1016/j.bbadis.2023.16671437028606
     [Google Scholar]
  151. WangZ. LiuF. WeiM. QiuY. MaC. ShenL. HuangY. Chronic constriction injury-induced microRNA-146a-5p alleviates neuropathic pain through suppression of IRAK1/TRAF6 signaling pathway.J. Neuroinflammation201815117910.1186/s12974‑018‑1215‑429885668
     [Google Scholar]
  152. PangB. QiaoL. WangS. GuoX. XieY. HanL. MiR-214-3p plays a protective role in diabetic neuropathic rats by regulating Nav1.3 and TLR4.Cell Biol. Int.202145112294230310.1002/cbin.1167734296787
     [Google Scholar]
  153. WuY. GuY. ShiB. miR-590-3p Alleviates diabetic peripheral neuropathic pain by targeting RAP1A and suppressing infiltration by the T cells.Acta Biochim. Pol.202067458759310.18388/abp.2020_545133332780
     [Google Scholar]
  154. ReidK.M. Sanchez-NietoJ.M. TerrasseS. FaccendaD. PernauteB. CampanellaM. RodriguezT.A. CobbB.S. MicroRNAs Regulate Ca2+ homeostasis in murine embryonic stem cells.Cells20231215195710.3390/cells1215195737566036
     [Google Scholar]
  155. MottiD. LerchJ.K. DanziM.C. GansJ.H. KuoF. SlepakT.I. BixbyJ.L. LemmonV.P. Identification of mi RNA s involved in DRG neurite outgrowth and their putative targets.FEBS Lett.2017591142091210510.1002/1873‑3468.1271828626869
     [Google Scholar]
  156. SunW. ZhangL. LiR. Overexpression of miR-206 ameliorates chronic constriction injury-induced neuropathic pain in rats via the MEK/ERK pathway by targeting brain-derived neurotrophic factor.Neurosci. Lett.2017646687410.1016/j.neulet.2016.12.04728130187
     [Google Scholar]
  157. ZhangP. WangC. LiC. WangJ. miR-34a-5p predicts the risk of diabetic neuropathic pain and mediates neuroinflammation in microglia via targeting ENPP3.Immunol. Invest.20245381348135810.1080/08820139.2024.240055039252196
     [Google Scholar]
  158. KongJ. LiuL. SongL. ZhaoR. FengY. MicroRNA miR-34a-5p inhibition restrains oxidative stress injury of macrophages by targeting MDM4.Vascular202331360861810.1177/1708538121106944735226569
     [Google Scholar]
  159. LiM. LiH. LiuX. XuD. WangF. MicroRNA-29b regulates TGF-β1-mediated epithelial–mesenchymal transition of retinal pigment epithelial cells by targeting AKT2.Exp. Cell Res.2016345211512410.1016/j.yexcr.2014.09.02625263462
     [Google Scholar]
  160. CiccacciC. MorgantiR. Di FuscoD. D’AmatoC. CacciottiL. GrecoC. RufiniS. NovelliG. SangiuoloF. MarfiaG.A. BorgianiP. SpalloneV. Common polymorphisms in MIR146a, MIR128a and MIR27a genes contribute to neuropathy susceptibility in type 2 diabetes.Acta Diabetol.201451466367110.1007/s00592‑014‑0582‑224682535
     [Google Scholar]
  161. PionaC. CostantiniS. ZusiC. CozziniT. PedrottiE. MariglianoM. FornariE. MaguoloA. MorandiA. MaffeisC. Early marker of ocular neurodegeneration in children and adolescents with type 1 diabetes: The contributing role of polymorphisms in mir146a and mir128a genes.Acta Diabetol.202259121551156110.1007/s00592‑022‑01919‑736002591
     [Google Scholar]
  162. ChangW.W. WenL.Y. ZhangL. TongX. JinY.L. ChenG.M. Association of rs2910164 in miR-146a with type 2 diabetes mellitus: A case–control and meta-analysis study.Front. Endocrinol.20221396163510.3389/fendo.2022.96163536237193
     [Google Scholar]
  163. LiY. MaW. XieC. ZhangM. YinX. WangF. XuJ. ShiB. Identification of genes and signaling pathways associated with diabetic neuropathy using a weighted correlation network analysis.Medicine20169547e544310.1097/MD.000000000000544327893688
     [Google Scholar]
  164. LiuJ.C. XueD.F. WangX.Q. AiD.B. QinP.J. MiR-101 relates to chronic peripheral neuropathic pain through targeting KPNB1 and regulating NF-κB signaling.Kaohsiung J. Med. Sci.201935313914510.1002/kjm2.1202530887716
     [Google Scholar]
  165. AshjariD. KaramaliN. RajabinejadM. HassaniS.S. Afshar HezarkhaniL. AfshariD. Gorgin KarajiA. SalariF. RezaiemaneshA. The axis of long non-coding RNA MALAT1/miR-1-3p/CXCR4 is dysregulated in patients with diabetic neuropathy.Heliyon202283e0917810.1016/j.heliyon.2022.e0917835368523
     [Google Scholar]
  166. LeindersM. ÜçeylerN. PritchardR.A. SommerC. SorkinL.S. Increased miR-132-3p expression is associated with chronic neuropathic pain.Exp. Neurol.2016283Pt A27628610.1016/j.expneurol.2016.06.02527349406
     [Google Scholar]
  167. HeynJ. LuchtingB. HinskeL.C. HübnerM. AzadS.C. KrethS. miR-124a and miR-155 enhance differentiation of regulatory T cells in patients with neuropathic pain.J. Neuroinflammation201613124810.1186/s12974‑016‑0712‑627646435
     [Google Scholar]
  168. FangY. SunS. WuJ. LiuG. WuQ. RanX. Alterations in the levels of urinary exosomal microrna-183-5p and microrna-125a-5p in individuals with type 2 diabetes mellitus.Biomedicines20241211260810.3390/biomedicines1211260839595174
     [Google Scholar]
  169. SahaP. YarraS.S. ArruriV. MohanU. KumarA. Exploring the role of mirna in diabetic neuropathy: From diagnostics to therapeutics.Naunyn Schmiedebergs Arch. Pharmacol.202439249503
     [Google Scholar]
  170. XourgiaE. PapazafiropoulouA. MelidonisA. Circulating microRNAs as biomarkers for diabetic neuropathy: A novel approach.World J. Exp. Med.201883182310.5493/wjem.v8.i3.1830596030
     [Google Scholar]
  171. SzydełkoJ. CzopM. PetniakA. Lenart-LipińskaM. KockiJ. ZapolskiT. Matyjaszek-MatuszekB. Identification of plasma miR-4505, miR-4743-5p and miR-4750-3p as novel diagnostic biomarkers for coronary artery disease in patients with type 2 diabetes mellitus: A case-control study.Cardiovasc. Diabetol.202423127810.1186/s12933‑024‑02374‑039080630
     [Google Scholar]
  172. MominM.Y. GaddamR.R. KravitzM. GuptaA. VikramA. The challenges and opportunities in the development of microrna therapeutics: A multidisciplinary viewpoint.Cells20211011309710.3390/cells1011309734831320
     [Google Scholar]
  173. AndersenH.H. DurouxM. GazeraniP. MicroRNAs as modulators and biomarkers of inflammatory and neuropathic pain conditions.Neurobiol. Dis.20147115916810.1016/j.nbd.2014.08.00325119878
     [Google Scholar]
  174. BanackS.A. DunlopR.A. MehtaP. MitsumotoH. WoodS.P. HanM. CoxP.A. A microRNA diagnostic biomarker for amyotrophic lateral sclerosis.Brain Commun.202465fcae26810.1093/braincomms/fcae26839280119
     [Google Scholar]
  175. LiX. DaiA. TranR. WangJ. Text mining-based identification of promising miRNA biomarkers for diabetes mellitus.Front. Endocrinol.202314119514510.3389/fendo.2023.119514537560309
     [Google Scholar]
  176. AghamiriS. TalaeiS. GhavidelA.A. ZandsalimiF. MasoumiS. HafshejaniN.H. JajarmiV. Nanoparticles-mediated CRISPR/Cas9 delivery: Recent advances in cancer treatment.J. Drug Deliv. Sci. Technol.20205610153310.1016/j.jddst.2020.101533
     [Google Scholar]
  177. CondratC.E. ThompsonD.C. BarbuM.G. BugnarO.L. BobocA. CretoiuD. SuciuN. CretoiuS.M. VoineaS.C. Mirnas as biomarkers in disease: Latest findings regarding their role in diagnosis and prognosis.Cells20209227610.3390/cells902027631979244
     [Google Scholar]
  178. IjeeS. ChambayilK. ChaudhuryA.D. BagchiA. ModakK. DasS. BenjaminE.S.B. RaniS. PaulD.Z. NathA. RoyD. PalaniD. PriyankaS. RavichandranR. KumaryB.K. SivamaniY. SV. BabuD. NakamuraY. ThamodaranV. BalasubramanianP. VelayudhanS.R. Efficient deletion of microRNAs using CRISPR/Cas9 with dual guide RNAs.Front. Mol. Biosci.202410129550710.3389/fmolb.2023.129550738628442
     [Google Scholar]
  179. ChenQ. ChenJ. LiuY.N. QiS.H. HuangL.Y. Exosome-based drug delivery systems for the treatment of diabetes and its complications: Current opinion.Extracellular Vesicles and Circulating Nucleic Acids20234350251710.20517/evcna.2023.3239698026
     [Google Scholar]
  180. LeeS.W.L. PaolettiC. CampisiM. OsakiT. AdrianiG. KammR.D. MattuC. ChionoV. MicroRNA delivery through nanoparticles.J. Control. Release2019313809510.1016/j.jconrel.2019.10.00731622695
     [Google Scholar]
  181. LamJ.K.W. ChowM.Y.T. ZhangY. LeungS.W.S. Sirna versus mirna as therapeutics for gene silencing.Mol. Ther. Nucleic Acids201549e25210.1038/mtna.2015.2326372022
     [Google Scholar]
  182. ChehelgerdiM. ChehelgerdiM. AllelaO.Q.B. PechoR.D.C. JayasankarN. RaoD.P. ThamaraikaniT. VasanthanM. ViktorP. LakshmaiyaN. SaadhM.J. AmajdA. Abo-ZaidM.A. Castillo-AcoboR.Y. IsmailA.H. AminA.H. Akhavan-SigariR. Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation.Mol. Cancer202322116910.1186/s12943‑023‑01865‑037814270
     [Google Scholar]
  183. TajabadiZ. DadkhahP. Gholami ChahkandM.S. Esmaeilpour MoallemF. KarimiM.A. Amini-SalehiE. KarimiM. Exploring the role of exosomes in diabetic neuropathy: From molecular mechanisms to therapeutic potential.Biomed. Pharmacother.202518511795910.1016/j.biopha.2025.11795940056828
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998375284250905115146
Loading
Clinical Importance of miRNA in Diabetic Neuropathy: Pathophysiology, Diagnosis, and Therapeutic Potential
Curr. Diabetes Rev. 22, E15733998375284 (2026); https://doi.org/10.2174/0115733998375284250905115146
/content/journals/cdr/10.2174/0115733998375284250905115146
/content/journals/cdr/10.2174/0115733998375284250905115146
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Diabetic neuropathy; microRNA; microvascular endothelial communication networks; neurodegenerative disease; neurovascular dysfunction; pathophysiology; therapeutic potential

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test